hotspot -WSS

hotspot

author：hotspot 2025-10-02 20:47:18 - browse：5416

Nick Leschly - Bluebird Bio — Longtime Bluebird Bio CEO Nick Leschly Wendy Maeda/The Boston Globe

Some two years after splitting biotech company Bluebird Bio into two entities in a bid to “sharpen their focus” and improve operations, the spinout focused on oncology treatments announced major cost cuts and is parting ways with its chief executive.

The spinout, 2Seventy Bio, announced Tuesday that it is cutting approximately 40% of its workforce, or about 176 employees. It also plans to allocate less money to a couple of drug candidates, including one that is currently on hold with the Food and Drug Administration. The cuts extend the company’s cash runway into 2026.

The company was formed in 2021 when the team behind Bluebird Bio decided to split its drug pipeline down the middle. The company was wrestling with its gene therapy portfolio, including getting approval for a gene therapy for the blood disorder beta thalassemia in the U.S. Separately, it had a basket of cancer drug candidates and a partnership with pharma company Bristol Myers Squibb that needed attention. So, Bluebird split its operations in two, with longtime CEO Nick Leschly taking the helm at the new firm.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Flash flood warnings continue for parts of Missouri, Illinois

knowledge

WSS

The wait for US passports is creating travel purgatory and snarling summer plans

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

Judge in Trump's classified documents case questions use of out

Tuberculosis patients need more than just free medication

Trump used to be more articulate. What could explain the change?

Failure, not just success, should guide future doctors

focus

hotspot

entertainment

Sports medicine is finally prioritizing gender equality

Beware reading your test results before your doctor does

Duchenne breakthrough therapy leaves behind pioneering families

UpToDate has a racism problem: Dr. Stanley Goldfarb

DIEP, the 'gold standard' of breast reconstruction, is under threat

{$content}

Cancer drug shortages should be causing more outrage

What affirmative action's end means to a medical student

Jerome Adams on the need for new antivirals for Covid

Flash flood warnings continue for parts of Missouri, Illinois

hotspot

Judge in Trump's classified documents case questions use of out

Penis shrinkage, a side effect of prostate cancer surgery, is temporary

Beware reading your test results before your doctor does

Undocumented workers face uncertainty as immigration law takes effect in Florida

UpToDate has a racism problem: Dr. Stanley Goldfarb

Doctors are clamoring for more clarity on Paxlovid prescribing

hotspot

knowledge

focus

hotspot